{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:13:35Z","timestamp":1768306415641,"version":"3.49.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Central nervous system lymphoma (CNSL) is a rare but aggressive subtype of lymphoma that presents significant therapeutic challenges. The prognosis for patients with CNSL varies significantly based on several genetic factors, including TP53 mutations, which are among the most critical determinants of treatment outcomes. Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results in several hematological malignancies, including B-cell lymphomas. However, its efficacy in CNSL, particularly in patients with TP53 mutations, requires further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted on 61 CNSL patients who had been treated at our institution from 2020 to 2024. The median follow-up time was 14.5\u202fmonths. A total of 43 patients received CAR-T cell infusion therapy. The overall survival (OS) and progression-free survival (PFS) of patients harboring TP53 mutations (TP53+) and those with wild-type TP53 (TP53\u2212) were compared. In addition, factors associated with patient prognosis were also identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 43 patients who received CAR-T cell therapy, 17 harbored TP53 mutations. The median age of the cohort was 51.5\u202fyears, and 51.2% of the patients (22\/43) were male. The overall response rate (ORR) and the complete response rate (CRR) in the TP53+ CAR-T+ group were both 64.5% (11\/17), the median OS duration was 14.07\u202fmonths (95% CI 12.63\u2013\u221e), and the median PFS duration was 12.77\u202fmonths (95% CI 6.33\u2013\u221e). In the TP53-CAR-T+ group, the ORR was 73.3% (19\/26), the CRR was 69.2% (18\/26), the median OS duration was 33.47\u202fmonths (95% CI 11.23\u2013\u221e), and the median PFS duration was 22.4\u202fmonths (95% CI 6.13\u2013\u221e). In the subgroup analysis, the cell-of-origin (COO) classification was a key factor influencing the long-term survival of CSNL patients; in the TP53+ group, patients with non-germinal center B-cell-like (GCB) classification had longer OS compared to the GCB subtype (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR-T cell therapy is an effective treatment for CNSL patients harboring TP53 mutations and has the same efficacy as traditional treatment methods. Additionally, CAR-T cells may be more effective for TP53+ CSNL patients with a non-GCB classification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1731589","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:33:53Z","timestamp":1768286033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier"],"prefix":"10.3389","volume":"12","author":[{"given":"Danyang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.21873\/anticanres.17107","article-title":"Comparative study on the clinicopathologic and molecular characteristics of primary and secondary diffuse large B-cell lymphoma in the central nervous system","volume":"44","author":"Do","year":"2024","journal-title":"Anticancer Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances","volume":"65","author":"Schaff","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40478-016-0307-6","article-title":"TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy","volume":"4","author":"Munch-Petersen","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12885-022-09275-z","article-title":"The PI3K\/AKT\/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1158\/2159-8290.CD-17-0714","article-title":"Spotlight on ibrutinib in PCNSL: adding another feather to its cap","volume":"7","author":"Lakshmanan","year":"2017","journal-title":"Cancer Discov"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/978-3-031-23705-8_20","article-title":"Lymphomas of central nervous system","volume":"1405","author":"Yokogami","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","article-title":"Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?","volume":"29","author":"Thomas","year":"2022","journal-title":"Cell Death Differ"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"jcs237453","DOI":"10.1242\/jcs.237453","article-title":"p53, cancer and the immune response","volume":"133","author":"Blagih","year":"2020","journal-title":"J Cell Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","article-title":"Emerging roles of p53 and other tumour-suppressor genes in immune regulation","volume":"16","author":"Munoz-Fontela","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/bloodadvances.2024014460","article-title":"Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma","volume":"9","author":"Geng","year":"2025","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/oncolo\/oyac190","article-title":"Genomic profiling reveals differences in primary central nervous system lymphoma and large B-cell lymphoma, with subtyping suggesting sensitivity to BTK inhibition","volume":"28","author":"Severson","year":"2023","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00277-023-05420-1","article-title":"Prognostic impact of MYD88 and TP53 mutations in diffuse large B cell lymphoma","volume":"102","author":"Ebid","year":"2023","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00277-025-06297-y","article-title":"TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy","volume":"104","author":"Katagiri","year":"2025","journal-title":"Ann Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12964-024-01765-w","article-title":"Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms","volume":"22","author":"Du","year":"2024","journal-title":"Cell Commun Signal"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.3390\/cancers13225592","article-title":"Influence of TP53 mutation on survival of diffuse large B-cell lymphoma in the CAR T-cell era","volume":"13","author":"Porpaczy","year":"2021","journal-title":"Cancers"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.62347\/LHIO8294","article-title":"Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets","volume":"14","author":"Wen","year":"2024","journal-title":"Am J Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1532460","DOI":"10.3389\/fimmu.2025.1532460","article-title":"Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory\/relapsed B-cell lymphoma: a single-arm clinical study","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1566938","DOI":"10.3389\/fonc.2025.1566938","article-title":"CAR T-cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1647737","DOI":"10.3389\/fmed.2025.1647737","article-title":"Nanotechnology and natural killer cell immunotherapy: synergistic approaches for precise immune system adjustment and targeted cancer treatment in gastrointestinal tumors","volume":"12","author":"Kang","year":"2025","journal-title":"Front Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1655693","DOI":"10.3389\/fmed.2025.1655693","article-title":"Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges\u2014a mini review","volume":"12","author":"Zhao","year":"2025","journal-title":"Front Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/vaccines13040337","article-title":"The application of dendritic cells vaccines in tumor therapy and their combination with biomimetic nanoparticles","volume":"13","author":"Zhu","year":"2025","journal-title":"Vaccines"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1731589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:33:53Z","timestamp":1768286033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1731589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1731589"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1731589","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1731589"}}